RSS
24 Dec 2020

Estudo de fase 2/3 para COVID-19 da RedHill com opaganibe passa pela segunda recomendação unânime do DSMB para continuar

Author: admintech | Filed under: Press Release

TEL AVIV, Israel e RALEIGH, N.C., 24 de dezembro de 2020 /PRNewswire/ — A RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” ou a “empresa”), uma empresa biofarmacêutica especializada, anunciou hoje que o estudo global de Fase 2/3 com opaganibe (Yeliva®, ABC294640)[1] administrado…

This entry was posted on Thursday, December 24th, 2020 at 2:02 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»